{
    "root": "955dd6eb-46f6-4c73-bcc8-bfd7b14ebc98",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Roflumilast"
    },
    "value": "20250313",
    "ingredients": [
        {
            "name": "ROFLUMILAST",
            "code": "0P6C6ZOP5U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "Roflumilast tablets is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.\n                  \n                     Limitations of Use\n                     Roflumilast tablets is not a bronchodilator and is not indicated for the relief of acute bronchospasm.\n                  Roflumilast tablets 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.",
    "contraindications": "The maintenance dose of roflumilast tablets is one 500 micrograms (mcg) tablet per day, with or without food. \n                  Starting treatment with a dose of Roflumilast tablets 250 mcg once daily for 4 weeks and increasing to Roflumilast tablets 500 mcg once daily thereafter may reduce the rate of treatment discontinuation in some patients [see Clinical Studies (14.1)]. However, 250 mcg per day is not the effective (therapeutic) dose.",
    "warningsAndPrecautions": null,
    "adverseReactions": "The use of roflumilast tablets is contraindicated in the following condition: Moderate to severe liver impairment (Child-Pugh B or C) [see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6)]."
}